Arrow
Arrow
Slider

Publications

 

  1. Winiarska M, Nowis D, Firczuk M, Zagozdzon A, Gabrysiak M, Sadowski R, Barankiewicz J, Dwojak M, Golab J. Selection of an optimal promoter for gene transfer in normal B cells. Mol Med Rep. 2017 Sep;16(3):3041-3048. doi: 10.3892/mmr.2017.6974. Epub 2017 Jul 14.
  2. Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, Dalla Venezia N, Kozikowski M, Siernicka M, Miazek N, Zapala P, Domagala A, Bojarczuk K, Malenda A, Barankiewicz J, Graczyk-Jarzynka A, Zagozdzon A, Gabrysiak M, Diaz JJ, Karp M, Lech-Maranda E, Firczuk M, Giannopoulos K, Efremov DG, Laurenti L, Baatout D, Frenzel L, Malinowska A, Slabicki M, Zenz T, Zerrouqi A, Golab J, Winiarska M. “HDAC6 inhibition up-regulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies” Blood. 2017 Oct 5;130(14):1628-1638.
  3. Słabicki M, Lee KS, Jethwa A, Sellner L, Sacco F, Walther T, Hüllein J, Dietrich S, Wu B, Lipka DB, Oakes CC, Mamidi S, Pyrzyńska B, Winiarska M, Oleś M, Seifert M, Plass C, Kirschfink M, Boettcher M, Gołąb J, Huber W, Fröhling S, Zenz T. Dissection of CD20 regulation in lymphoma using RNAi. Leukemia. 2016 Dec;30(12):2409-2412.
  4. Gabrysiak M, Wachowska M, Barankiewicz J, Pilch Z, Ratajska A, Skrzypek E, Winiarska M, Domagala A, Rygiel TP, Jozkowicz A, Boon L, Golab J, Firczuk M. Low dose of GRP78-targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo. Oncol Rep. 2016 Jun;35(6):3151-8. doi: 10.3892/or.2016.4723
  5. Trzeciecka A, Klossowski S, Bajor M, Zagozdzon R, Gaj P, Muchowicz A, Malinowska A, Czerwoniec A, Barankiewicz J, Domagala A, Chlebowska J, Prochorec-Sobieszek M, Winiarska M, Ostaszewski R, Gwizdalska I, Golab J, Nowis D, Firczuk M. Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma. Oncotarget. 2015 Nov 30. doi: 10.18632/oncotarget.6435.
  6. Siernicka M, Winiarska M, Bajor M, Firczuk M, Muchowicz A, Bobrowicz M, Fauriat C, Golab J, Olive D, Zagozdzon R. “Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells” Immunology. 2015 Sep;146(1):173-83.
  7. Dwojak M, Bobrowicz M, Bil J, Bojarczuk K, Pyrzynska B, Siernicka M, Malenda A, Lech-Maranda E, Tomczak W, Giannopoulos K, Golab J, Winiarska M. “Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulating proteins” Blood Cancer J. 2015 Apr 10;5:e300
  8. Dudek-Peric AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Matrin S, Kiviluoto S, Winiarska M, Boon L, Mathieu C, van den Oord J, Stas M, Gougeon ML, Golab J, Garg AD, Agostinis P. ”Anti-tumor immunity triggered by melphalan is potentiated by melanoma cell surface associated calreticulin” Cancer Res. 2015 Mar 11. pii: canres.2089.2014.
  9. Winiarska M, Bojarczuk K, Pyrzynska B, Bil J, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P, Zagozdzon A, Krol M, Syta A, Podszywalow-Bartnicka P, Pilch Z, Dabrowska-Iwanicka A, Juszczynski P, Efremov DG, Slabicki M, Zenz T, Le Roy A, Olive D, Rygiel TP, Leusen JH, Golab J. “Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies” mAbs 6:5, 1–13; September/October 2014
  10. Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, Karp M, Giannopoulos K, Efremov DG, Fauriat C, Golab J and Winiarska M. “B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies” Leukemia. 2014 May;28(5):1163-7
  11. Firczuk M, Gabrysiak M, Barankiewicz J, Domagala A, Nowis D, Kujawa M, Jankowska-Steifer E, Wachowska M, Glodkowska-Mrowka E, Korsak B, Winiarska M, Golab J. “GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy” Cell Death Dis. 2013 Jul 25;4:e741.
  12. Malenda A, Skrobanska A, Issat T, Winiarska M, Bil J, Oleszczak B, Sinski M, Firczuk M, Bujnicki JM, Chlebowska J, Staruch AD, Glodkowska-Mrowka E, Kunikowska J, Krolicki L, Szablewski L, Gaciong Z, Koziak K, Jakobisiak M, Golab J, Nowis DA. „Statins impair glucose uptake in tumor cells” Neoplasia April 2012; Vol. 14, No. 4
  13. Winiarska M, Nowis D, Bil J, Glodkowska-Mrowka E, Muchowicz A, Wanczyk M, Bojarczuk K, Dwojak M, Firczuk M, Wilczek E, Wachowska M, Roszczenko K, Miaczynska M, Chlebowska J, Basak GW, Golab J. „Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity” J Biol Chem. 2012 Sep 14;287(38):31983-93. Epub 2012 Jul 26
  14. Wilczek E, Szparecki G, Lukasik D, Koperski L, Winiarska M, Wilczynski GM, Wasiutynski A, Gornicka B. “Loss of the orphan nuclear receptor SHP is more pronounced in fibrolamellar carcinoma than in typical hepatocellular carcinoma” PLoS One. 2012;7(1):e30944. Epub 2012 Jan 23
  15. Bil J, Winiarska M, Nowis D, Bojarczuk K, Dąbrowska-Iwanicka A, Basak GW, Sułek K, Jakobisiak M, Golab J.
    “Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity” Blood. 2010 May 6;115(18):3745-55.
  16. Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, Mackus WJM, Gorska E, Bojarski L, Stoklosa T, Nowis D, Kurzaj Z, Makowski M, Glodkowska E, Issat T, Mrowka P, Lasek W, Dabrowska-Iwanicka A, Basak GW, Wasik M, Warzocha K, Sinski M, Gaciong Z, Jakobisiak M, Parren PWHI, Golab J. “Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20” PLoS Med. 2008 Mar 25;5(3):e64

 

OPEN